Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.

To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable mutations.Using a nationally...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Amy P Abernethy, Ashwini Arunachalam, Thomas Burke, Caroline McKay, Xiting Cao, Rachael Sorg, David P Carbone
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science (PLoS) 2017-01-01
Edice:PLoS ONE
On-line přístup:http://europepmc.org/articles/PMC5482433?pdf=render
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky